Document is current

Article History

Received: 17 February 2021

Accepted: 24 August 2021

First Online: 5 September 2021

Declarations

:

: The study setting and research process complied with local and national ethical instructions for research [CitationRef removed]. The participants of the StopDia study have provided written informed consent to take part in the study and to connect the national registry information into their follow-up data. The Kuopio University Hospital (KUH) ethical board has processed the ethical application and granted a permit (467/2016) to perform the study. The StopDia study was conducted according to the Responsible Conduct of Research guidelines by the Finnish Advisory Board on Research Integrity, and the Declaration of Helsinki. Use of register data for the incidence of T2D complications and additional T2D health care costs for basic health care was approved by the Ethics Committee of the Northern Savonia Hospital District (diary number 81/2012). The study protocol was also approved by the register administrator, the Joint Municipal Authority for North Karelia Social and Health Services (Siun Sote). Only register-based data were utilized and, therefore, consent from the patients was not needed.

: Not applicable.

: Martikainen J is a founding partner of ESiOR Oy and a board member of Siltana Oy. Aarnio E has received a consulting fee from Merck & Co. These companies were not involved in carrying out this research. Jalkanen K declares no competing interests, Lavikainen P declares no competing interests, Lindström J declares no competing interests, Peltonen M declares no competing interests, Laatikainen T declares no competing interests.